#######Page
*T!^&*#*((*!#&()#_)#!*&$!*#)(!*Week_6_Medication_Table.docx10/16/2026,
Page11@~!@#########################Page
of 1510/16/2026, 5:42:03 AM*&!#%#&&!%%#^#^&^!#&*^&^*#!(FG*T!^&*#*((*!#&()#_)#!*&$!*#)(!*Week_6_Medication_Table.docx10/16/2026,
1 of 1510/16/2026,
5:42:03
5:42:03
AM*&!#%#&&!%%#^#^&^!#&*^&^*#!(FG*T!^&*#*((*!#&()#_)#!*&$!*#)(!*##(*0Week_6_Medication_Table.docx.pdf*&!#%#&&!%%#^#
AM*&!#%#&&!%%#^#^&^!#&*^&^*#!(FG*T!^&*#*((*!#&()#_)#!*&$!*#)(!*Week_6_Medication_Table.docx10/16/2026,
5:42:03 AM*&!#%#&&!%%#^#^&^!#&*^&^*#!(FG*T!^&*#*((*!#&()#_
5:42:03 AM*&!#%#&
Addiction Medications Table
Week 6
THIS ASSIGNMENT SHOULD BE SUBMITTED TO THE WEEK 6 MEDICATION TABLE DROPBOX BY SUNDAY AT 11:59 P.M. MT.
Drug Name Indication Half-life (T1/2), Notable Side Effects Initial Dosing Considerations
Neurotransmitter(s) Metabolism (CYP (link to NT or Specific lifespan
Affected 450 enzyme) affected brain circuit) considerations (age,
Target Symptoms pregnancy, breastfeeding)
Buprenorphine Indication (bold for Half-life (T1/2): Notable Side Effects Initial Dosing Considerations:
(Subutex) FDA approved): Elimination half life (link to NT or Sublingual: 8-32 mg/day
p.113 Maintenance of sublingual affected brain Day 1:
treatment of buprenorphine is circuit): 8mg, Day 2:
opioid dependence 24 to 42 hours. Binds at mu opioid 12 or 16 mg
(sublingual) Implant T Max is 12 receptor sites Day 3-7:
Moderate to sever hours, time to Increase in increments of 4
opioid use disorder steady state is 4 Headache, mg; max 32mg.
in patients who weeks. constipation, nausea Sublocade injection:
have initiated Injection. Time to Oral hypoesthesia, maintenance dose is 100-300
treatment with a steady state is 4 to glossodynia. mg monthly
transmucosal 6 months; Plasma Othostatic Brixadi injection, weekly:
buprenorphine- levels may be hypotension maintenance dose is 24-32 mg
containing product, detectable for up weekly
followed by dose to 12 months Brixadi injection, monthly:
adjustment for a following maintenance dose is 64-128
minimum of 7 days discontinuation. mg monthly
(Sublocade) Correlation with
Moderate to urine consideration Specific lifespan
severe opioid use is not known. considerations (age,
disorder in patient pregnancy, breastfeeding):
who have initiated Metabolism (CYP
Chamberlain University | National Management Offices | 500 W. Monroe St., Suite 28 | Chicago, IL 60661
©2021 Chamberlain University LLC. All rights reserved.
f(*!#&()#_)#!*&$!*#)(!*Week_6_Medication_Table.docx10/16/2026,
1510/16/2026,
@~!@#########################Page
5:42:03 AM*&!#%#&&!%%#^#^&^!#&*^&^*#!(FG*T!^&*#*((*!#&()#_)#!*&$!*#)(!*Week_6_Medication_Table.docx10/16/2026,
1 of 1510/16/2026,
5:42:03
5:42:03
AM*&!#%#&&!%%#^#^&^!#&*^&^*#!(FG*T!^&*#*((*!#&()#_)#!*&$!*#)(!*##(*0Week_6_Medication_Table.docx.pdf*&!#%#&&!%%#^#^&^!#&*^
AM*&!#%#&&!%%#^#^&^!#&*^&^*#!(FG*T!^&*#*((*!#&()#_)#!*&$!*#)(!*Week_6_Medication_Table.docx10/16/2026,
5:42:03 AM*&!#%#&&!%%#^#^&^!#&*^&^*#!(FG*T!^&*#*((*!#&()#_)#!*&$!*#)(!*##(*0
5:42:03 AM*&!#%#&&!%%#
,#######Page
*T!^&*#*((*!#&()#_)#!*&$!*#)(!*Week_6_Medication_Table.docx10/16/2026,
Page22@~!@#########################Page
of 1510/16/2026, 5:42:03 AM*&!#%#&&!%%#^#^&^!#&*^&^*#!(FG*T!^&*#*((*!#&()#_)#!*&$!*#)(!*Week_6_Medication_Table.docx10/16/2026,
2 of 1510/16/2026,
5:42:03
5:42:03
AM*&!#%#&&!%%#^#^&^!#&*^&^*#!(FG*T!^&*#*((*!#&()#_)#!*&$!*#)(!*##(*0Week_6_Medication_Table.docx.pdf*&!#%#&&!%%#^#
AM*&!#%#&&!%%#^#^&^!#&*^&^*#!(FG*T!^&*#*((*!#&()#_)#!*&$!*#)(!*Week_6_Medication_Table.docx10/16/2026,
5:42:03 AM*&!#%#&&!%%#^#^&^!#&*^&^*#!(FG*T!^&*#*((*!#&()#_
5:42:03 AM*&!#%#&
Addiction Medications Table
Week 6
treatment with a 450 enzyme): Use caution in the elderly.
single dose of a Metabolized by Monitor patients for sedation
transcuosal CYP3A4. or respiratory depression.
nuptemrphine-
containing product Safety and efficacy have not
or who are already been established in children
being treated with and adolescents.
buprenorphine
(Brixadi) Controlled studies have not
been conducted in pregnant
Neurotransmitter(s) women.
Affected: Buprenorphine may be
Binds with strong preferable to methadone in
affinity to the mu pregnant women.
opioid receptor, Neonatal opioid withdrawal
preventing syndrome has been reported
exogenous opioids following use of
from bonding there buprenorphine during
and thus preventing pregnancy.
the pleasurable Not generally recommended
effects of opioid for use during pregnancy,
consumption. especially during first
Because trimester.
buprenorphine is a Some drug is found in breast
partial agonist, it milk.
can cause Recommended to either
immediate discontinue drug or formula
withdrawal and a feed.
patient currently
taking opioids. (i.e.,
reduces receptor
stimulation in the
Chamberlain University | National Management Offices | 500 W. Monroe St., Suite 28 | Chicago, IL 60661
©2021 Chamberlain University LLC. All rights reserved.
f(*!#&()#_)#!*&$!*#)(!*Week_6_Medication_Table.docx10/16/2026,
1510/16/2026,
@~!@#########################Page
5:42:03 AM*&!#%#&&!%%#^#^&^!#&*^&^*#!(FG*T!^&*#*((*!#&()#_)#!*&$!*#)(!*Week_6_Medication_Table.docx10/16/2026,
2 of 1510/16/2026,
5:42:03
5:42:03
AM*&!#%#&&!%%#^#^&^!#&*^&^*#!(FG*T!^&*#*((*!#&()#_)#!*&$!*#)(!*##(*0Week_6_Medication_Table.docx.pdf*&!#%#&&!%%#^#^&^!#&*^
AM*&!#%#&&!%%#^#^&^!#&*^&^*#!(FG*T!^&*#*((*!#&()#_)#!*&$!*#)(!*Week_6_Medication_Table.docx10/16/2026,
5:42:03 AM*&!#%#&&!%%#^#^&^!#&*^&^*#!(FG*T!^&*#*((*!#&()#_)#!*&$!*#)(!*##(*0
5:42:03 AM*&!#%#&&!%%#
*T!^&*#*((*!#&()#_)#!*&$!*#)(!*Week_6_Medication_Table.docx10/16/2026,
Page11@~!@#########################Page
of 1510/16/2026, 5:42:03 AM*&!#%#&&!%%#^#^&^!#&*^&^*#!(FG*T!^&*#*((*!#&()#_)#!*&$!*#)(!*Week_6_Medication_Table.docx10/16/2026,
1 of 1510/16/2026,
5:42:03
5:42:03
AM*&!#%#&&!%%#^#^&^!#&*^&^*#!(FG*T!^&*#*((*!#&()#_)#!*&$!*#)(!*##(*0Week_6_Medication_Table.docx.pdf*&!#%#&&!%%#^#
AM*&!#%#&&!%%#^#^&^!#&*^&^*#!(FG*T!^&*#*((*!#&()#_)#!*&$!*#)(!*Week_6_Medication_Table.docx10/16/2026,
5:42:03 AM*&!#%#&&!%%#^#^&^!#&*^&^*#!(FG*T!^&*#*((*!#&()#_
5:42:03 AM*&!#%#&
Addiction Medications Table
Week 6
THIS ASSIGNMENT SHOULD BE SUBMITTED TO THE WEEK 6 MEDICATION TABLE DROPBOX BY SUNDAY AT 11:59 P.M. MT.
Drug Name Indication Half-life (T1/2), Notable Side Effects Initial Dosing Considerations
Neurotransmitter(s) Metabolism (CYP (link to NT or Specific lifespan
Affected 450 enzyme) affected brain circuit) considerations (age,
Target Symptoms pregnancy, breastfeeding)
Buprenorphine Indication (bold for Half-life (T1/2): Notable Side Effects Initial Dosing Considerations:
(Subutex) FDA approved): Elimination half life (link to NT or Sublingual: 8-32 mg/day
p.113 Maintenance of sublingual affected brain Day 1:
treatment of buprenorphine is circuit): 8mg, Day 2:
opioid dependence 24 to 42 hours. Binds at mu opioid 12 or 16 mg
(sublingual) Implant T Max is 12 receptor sites Day 3-7:
Moderate to sever hours, time to Increase in increments of 4
opioid use disorder steady state is 4 Headache, mg; max 32mg.
in patients who weeks. constipation, nausea Sublocade injection:
have initiated Injection. Time to Oral hypoesthesia, maintenance dose is 100-300
treatment with a steady state is 4 to glossodynia. mg monthly
transmucosal 6 months; Plasma Othostatic Brixadi injection, weekly:
buprenorphine- levels may be hypotension maintenance dose is 24-32 mg
containing product, detectable for up weekly
followed by dose to 12 months Brixadi injection, monthly:
adjustment for a following maintenance dose is 64-128
minimum of 7 days discontinuation. mg monthly
(Sublocade) Correlation with
Moderate to urine consideration Specific lifespan
severe opioid use is not known. considerations (age,
disorder in patient pregnancy, breastfeeding):
who have initiated Metabolism (CYP
Chamberlain University | National Management Offices | 500 W. Monroe St., Suite 28 | Chicago, IL 60661
©2021 Chamberlain University LLC. All rights reserved.
f(*!#&()#_)#!*&$!*#)(!*Week_6_Medication_Table.docx10/16/2026,
1510/16/2026,
@~!@#########################Page
5:42:03 AM*&!#%#&&!%%#^#^&^!#&*^&^*#!(FG*T!^&*#*((*!#&()#_)#!*&$!*#)(!*Week_6_Medication_Table.docx10/16/2026,
1 of 1510/16/2026,
5:42:03
5:42:03
AM*&!#%#&&!%%#^#^&^!#&*^&^*#!(FG*T!^&*#*((*!#&()#_)#!*&$!*#)(!*##(*0Week_6_Medication_Table.docx.pdf*&!#%#&&!%%#^#^&^!#&*^
AM*&!#%#&&!%%#^#^&^!#&*^&^*#!(FG*T!^&*#*((*!#&()#_)#!*&$!*#)(!*Week_6_Medication_Table.docx10/16/2026,
5:42:03 AM*&!#%#&&!%%#^#^&^!#&*^&^*#!(FG*T!^&*#*((*!#&()#_)#!*&$!*#)(!*##(*0
5:42:03 AM*&!#%#&&!%%#
,#######Page
*T!^&*#*((*!#&()#_)#!*&$!*#)(!*Week_6_Medication_Table.docx10/16/2026,
Page22@~!@#########################Page
of 1510/16/2026, 5:42:03 AM*&!#%#&&!%%#^#^&^!#&*^&^*#!(FG*T!^&*#*((*!#&()#_)#!*&$!*#)(!*Week_6_Medication_Table.docx10/16/2026,
2 of 1510/16/2026,
5:42:03
5:42:03
AM*&!#%#&&!%%#^#^&^!#&*^&^*#!(FG*T!^&*#*((*!#&()#_)#!*&$!*#)(!*##(*0Week_6_Medication_Table.docx.pdf*&!#%#&&!%%#^#
AM*&!#%#&&!%%#^#^&^!#&*^&^*#!(FG*T!^&*#*((*!#&()#_)#!*&$!*#)(!*Week_6_Medication_Table.docx10/16/2026,
5:42:03 AM*&!#%#&&!%%#^#^&^!#&*^&^*#!(FG*T!^&*#*((*!#&()#_
5:42:03 AM*&!#%#&
Addiction Medications Table
Week 6
treatment with a 450 enzyme): Use caution in the elderly.
single dose of a Metabolized by Monitor patients for sedation
transcuosal CYP3A4. or respiratory depression.
nuptemrphine-
containing product Safety and efficacy have not
or who are already been established in children
being treated with and adolescents.
buprenorphine
(Brixadi) Controlled studies have not
been conducted in pregnant
Neurotransmitter(s) women.
Affected: Buprenorphine may be
Binds with strong preferable to methadone in
affinity to the mu pregnant women.
opioid receptor, Neonatal opioid withdrawal
preventing syndrome has been reported
exogenous opioids following use of
from bonding there buprenorphine during
and thus preventing pregnancy.
the pleasurable Not generally recommended
effects of opioid for use during pregnancy,
consumption. especially during first
Because trimester.
buprenorphine is a Some drug is found in breast
partial agonist, it milk.
can cause Recommended to either
immediate discontinue drug or formula
withdrawal and a feed.
patient currently
taking opioids. (i.e.,
reduces receptor
stimulation in the
Chamberlain University | National Management Offices | 500 W. Monroe St., Suite 28 | Chicago, IL 60661
©2021 Chamberlain University LLC. All rights reserved.
f(*!#&()#_)#!*&$!*#)(!*Week_6_Medication_Table.docx10/16/2026,
1510/16/2026,
@~!@#########################Page
5:42:03 AM*&!#%#&&!%%#^#^&^!#&*^&^*#!(FG*T!^&*#*((*!#&()#_)#!*&$!*#)(!*Week_6_Medication_Table.docx10/16/2026,
2 of 1510/16/2026,
5:42:03
5:42:03
AM*&!#%#&&!%%#^#^&^!#&*^&^*#!(FG*T!^&*#*((*!#&()#_)#!*&$!*#)(!*##(*0Week_6_Medication_Table.docx.pdf*&!#%#&&!%%#^#^&^!#&*^
AM*&!#%#&&!%%#^#^&^!#&*^&^*#!(FG*T!^&*#*((*!#&()#_)#!*&$!*#)(!*Week_6_Medication_Table.docx10/16/2026,
5:42:03 AM*&!#%#&&!%%#^#^&^!#&*^&^*#!(FG*T!^&*#*((*!#&()#_)#!*&$!*#)(!*##(*0
5:42:03 AM*&!#%#&&!%%#
